{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-21-106641","form_type":"8-K","ticker":"ELOX","cik":"0001035354","company_name":"Eloxx Pharmaceuticals, Inc.","filed_at":"2021-08-17T23:59:59+00:00","discovered_at":"2026-05-14T18:04:16.923482+00:00","generated_at":"2026-06-29T09:26:36.415923+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Eloxx reports Q2 net loss of $36.1M, cash $56.7M; CF trial on track for Q4 data","bullets":["Net loss $36.1M ($0.54/sh) vs $7.9M ($0.20/sh) in Q2 2020; includes $22.7M acquired IPR&D from Zikani.","Cash and equivalents $56.7M at June 30, 2021, expected to fund operations into Q1 2023.","ELX-02 Phase 2 CF monotherapy data on track for Q4 2021; combination arm with ivacaftor to start by end of 2021.","ZKN-013 nominated as lead candidate for RDEB/JEB; IND-enabling GLP studies expected by end of 2021.","Received up to $2.6M award from Cystic Fibrosis Foundation for oral ribosome modulating agents."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-21-106641","json":"https://secwatch.observer/filing/0001104659-21-106641.json","markdown":"https://secwatch.observer/filing/0001104659-21-106641.md","text":"https://secwatch.observer/filing/0001104659-21-106641.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1035354/000110465921106641/0001104659-21-106641-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1035354/000110465921106641/tm2125273d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-29T09:26:36.415923+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}